End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This retrospective analysis of GOYA aimed to assess t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Kostakoglu, Lale, Martelli, Maurizio, Sehn, Laurie H., Belada, David, Carella, Angelo-Michele, Chua, Neil, Gonzalez-Barca, Eva, Hong, Xiaonan, Pinto, Antonio, Shi, Yuankai, Tatsumi, Yoichi, Knapp, Andrea, Mattiello, Federico, Nielsen, Tina, Sahin, Deniz, Sellam, Gila, Oestergaard, Mikkel Z., Vitolo, Umberto, Trněný, Marek
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948296/
https://ncbi.nlm.nih.gov/pubmed/33651099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002690
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados